Response to CBC’s the Fifth Estate on the cost of medicines
Ottawa, December 15, 2016 – In response to CBC’s the fifth estate request for more information about the feasibility of a national pharmacare program and the cost of drugs in Canada, Innovative Medicines Canada issued the following statement:
“Innovative Medicines Canada and its member-companies are proud to be an integral part of our country’s healthcare system, and we believe that all Canadians deserve fair, equitable and affordable access to the medicines they need, when they need them.
“We are strongly committed to working collaboratively with governments and other healthcare stakeholders to develop sustainable solutions to ensure more timely and consistent patient access to medicines, including addressing gaps in care and access to treatment for those who cannot afford it. “Innovative medicines account for 6.4% of overall healthcare spending in Canada, but this investment has resulted in significantly improved health outcomes for patients across the country.
“For over 30 years, the Patented Medicines Prices Review Board (PMPRB) has controlled Canadian prices for innovative medicines at the time of launch and throughout their patent life. This has resulted in prices which by definition are not excessive compared to countries with similar economies to Canada.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information:
Tel.: 613-236-0455 ext. 217